Mycological aspects and susceptibility in vitro the yeast of the genus candida from hiv-positive patients in the state of mato grosso;Aspectos micológicos e suscetibilidade in vitro de leveduras do gênero candida em pacientes hiv-positivos provenientes do estado de mato grosso

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 43, Issue 6, 2010, Pages 673-677

  Favalessa, Olivia Cometti ^a   Martins, dos Anjos Marilena ^b   Hahn, E Rosane Christine ^a,c,d  

^a UNIVERSIDADE FEDERAL DE MATO GROSSO   (Brazil)

^b Inst Botanica CP 4005 01061 970   (Brazil)

^c HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

^d Hospital Geral Universitário Divisão de Odontologia   (Brazil)

Author keywords

Candida sp; HIV positive patients; In vitro susceptibility

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; EPSILOMETER TEST; FUNGAL EXAMINATION; FUNGAL MORPHOLOGY; FUNGUS GROWTH; FUNGUS IDENTIFICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 78650978675     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822010000600014     Document Type: Article

References (24)

1. Ministério da Saúde. Boletim Epidemiológico AIDS-DST. Brasília, DF: Ministério da Saúde; 2007. Disponível em http://www.aids.gov.br/data/Pages/.
2. Gonzales P, Pereira A, Pérez J, Noriega LM, Palavecino ES. Susceptibilidad antifúngica de Candida albicans recuperadas de pacientes com SIDA y candidiasis orofaríngea y esofágica. Experience com Etest Rev Med Chile 2003; 131:515-519.
3. Campos J, Del Romero J, Castilha J, Garcia S, Rodriguez C, Bascones A. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lynphocyte percentage in HIV-infected patients. J Oral Pathol Med 2002; 31:5-10.
4. Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KAS. Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. J Oral Pathol Med 2002; 1:169-174.
5. Wingeter MA, Guilhermetti E, Shinobu CS, Takaki I, Svidizinski TIE. Identificação microbiológica e sensibilidade in vitro de Candida isoladas da cavidade oral de indivíduos HIV positivos. Rev Soc Bras Med Trop 2007; 40:272-276.
6. Pfaller MA. Antifungal susceptibilidade testing methods. Curr Drugs Targets 2005; 6:929-943.
7. Ballesté R, Arteta Z, Barloco A, Mier C, Fernández N, Mousqués N, et al. Evaluación Del desempeño diagnóstico Del médio de difusión em Agar Etest para El estúdio de sensibilidad a los antifúngicos. Rev Med Urug 2006; 22:128-135.
8. CLSI.M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of 304 Yeasts. Third Edition. Clinical and Laboratory Standards Institute, Wayne, PA. 2008;305.
9. Vandenbossche I, Vaneechoutte M, Vandevenne M, De Baere T, Verschraegen G. Susceptibility testing of fluconazol by the NCCLS broth macrodilution method, E-Test, and disk diffusion for application in the routine laboratory. J Clin Microbiol 2002; 40:918-921.
10. Salobreña AC, Cepeda LAG, Cañada FO, Barrionuevo DO, García LC, Quindós G. Resistência in vitro a los antifúngicos en Candida albicans de pacientes infectados por el VIH con y sin candidosis oral. Rev Iberoam Micol 1999; 16:194-197.
11. Diz P, Ocampo A, Miralles C, Otero Y, Iglesias Y, Martínez C. Candidosis oroesofágica resistente AL fluconazol em pacientes com SIDA. Enfern Infecc Microbiol Clin 1993; 11:36-39.
12. Heinic GS, Stevens DA, Greenspan D, Macphail LA, Dodd CL, Stringari S, et al. Fluconazole-resistant Candida in AIDS patients: reports of two cases. Oral Surg Oral Med Oral Pathol 1993; 76:711-715.
13. Kurtzman CP, Fell JW. The yest. A taxonomic study. Elsevier: Amsterdam;1998.
14. Mannarelli BM, Kurtzman CP. Rapid identification of Candida albicans and other human pathogenic yeasts by using short oligonucleotides in a PCR. J Clin Microbiol 1998; 36:1634-1641.
15. Chavasco JK, Paula CR, Hirata MH, Aleva NA, Melo CR, Gambale W, et al. Molecular Identification of Candida dubliniensis isolated from oral lesions of HIV-negative patients in São Paulo, Brazil. Rev Inst Med Trop São Paulo 2006; 428:21-26.
16. AB BIODISK. Etest Technical guide 4b: Antifungical susceptibility testing of yeasts. Piscataway, New Jersey: AB BIODISK; 1994.
17. Sant'Ana PL, Milan EP, Martinez R, Queiros-Teles F, Ferreira MS, Alcântara AP, et al. Multicenter Brazilian Study of Oral Candida Species Isolated from Aids Patients. Mem Inst Oswaldo Cruz 2002; 97:253-257.
18. Barchiesi F, Maracci M, Radi B, Arzeni D, Baldassarri I, Giacometti A, et al. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2000; 50:999-1002.
19. Sánchez-Vargas LO, Ortiz-lópez GN, Villar M, Moragues MD, Aguirre JM, Cashat-cruz M, et al. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol 2005; 22:83-92.
20. Melo NR, Taguchi H, Jorge J, Pedro RJ, Almeida OP, Fukushima K, et al. Oral Candida flora from Brazilian human immunodeficiency virus-infected patients in the highly active antiretroviral therapy era. Mem Inst Oswaldo Cruz 2004; 99:425-431.
21. Gutiérrez C, Bedout C, Tobón AM, Cano LE, Arango M, Tabares AM, et al. Sensibilidad a fluconazol y voriconazol de aislamientos de Candida spp, obtenidos de mucosa oral de pacientes com sida. Infectio 2007; 11:183-189.
22. Silva MRR, Paula CR, Silva SC, Costa TR, Costa MR. Drug resistence of yeast isolated from oropharyngeal candidiasis in AIDS patients. Rev Microbiol 1998; 29:1-7.
23. Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against nom Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22:24-28.
24. Goldman M, Cloud GA, Smedema M, Lemonte A, Connolly P, Mckinsey D, et al. Does long-term itraconazole prophylaxis result in vitro azole resistance in mucosal Candida albicans isolates from persons which advanced human immunodeficiency virus infection? Antimicrob Agents Chemother 2000; 44:1585-1587.